NCT05294731 2026-04-17Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderBeOne MedicinesPhase 1/2 Recruiting146 enrolled
NCT03192397 2026-04-14Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantRoswell Park Cancer InstitutePhase 1/2 Active not recruiting35 enrolled 19 charts
NCT02213913 2026-03-11Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasUniversity of ChicagoPhase 1/2 Completed55 enrolled 17 charts
NCT07249905 2026-03-03Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaModeX Therapeutics, An OPKO Health CompanyPhase 1/2 Recruiting180 enrolled
NCT07420959 2026-02-19ABBV-383 for the Treatment of Relapsed Refractory Waldenström MacroglobulinemiaMayo ClinicPhase 1/2 Not yet recruiting38 enrolled
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 4 FDA